Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Free Report) saw a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 12,300,000 shares, a decline of 6.5% from the May 31st total of 13,160,000 shares. Based on an average trading volume of 4,550,000 shares, the short-interest ratio is presently 2.7 days.
Akebia Therapeutics Stock Performance
Shares of Akebia Therapeutics stock traded down $0.03 during trading hours on Tuesday, hitting $0.96. The company’s stock had a trading volume of 3,295,965 shares, compared to its average volume of 3,969,574. The business has a 50 day moving average price of $1.14 and a two-hundred day moving average price of $1.39. Akebia Therapeutics has a 12-month low of $0.78 and a 12-month high of $2.48. The company has a market cap of $201.22 million, a PE ratio of -4.17 and a beta of 0.78.
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). The business had revenue of $32.61 million during the quarter, compared to analysts’ expectations of $41.13 million. During the same quarter in the previous year, the firm earned ($0.14) earnings per share. As a group, research analysts anticipate that Akebia Therapeutics will post -0.28 earnings per share for the current year.
Institutional Investors Weigh In On Akebia Therapeutics
Analyst Upgrades and Downgrades
AKBA has been the topic of several analyst reports. StockNews.com downgraded Akebia Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 29th. HC Wainwright lifted their target price on Akebia Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Thursday, March 28th.
Check Out Our Latest Analysis on AKBA
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
Recommended Stories
- Five stocks we like better than Akebia Therapeutics
- Stock Market Upgrades: What Are They?
- RXO Shares Surge Following New Acquisition Deal
- What is the Nikkei 225 index?
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- The 3 Best Blue-Chip Stocks to Buy Now
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.